Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN73,8573,86-1,44
Msft0,58
Nokia4,6464,7770,34
IBM0,75
Mercedes-Benz Group AG51,4551,47-0,41
PFE0,99
07.06.2025 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 06.06.2025 21:59:42
Agilent Tech (A, NY Consolidated)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
115,81 1,64 1,87 1 219 514
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 07.06.2025
Popis společnosti
Obecné informace
Název společnostiAgilent Technologies Inc
TickerA
Kmenové akcie:Ordinary Shares
RICA
ISIN-
Poslední známé roční výsledky31.10.2024
Poslední známé čtvrtletní výsledky30.04.2025
Počet zaměstnanců k 30.04.2025 18 000
Akcie v oběhu k 23.05.2025 284 064 728
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice5301 Stevens Creek Blvd
MěstoSANTA CLARA
PSČ95051
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon14 083 458 886
Fax14083458474

Business Summary: Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Financial Summary: BRIEF: For the six months ended 30 April 2025, Agilent Technologies Inc revenues increased 4% to $3.35B. Net income decreased 19% to $533M. Revenues reflect Life Sciences and Diagnostics Markets segment increase of 6% to $1.3B, Agilent CrossLab segment increase of 4% to $1.41B, United States segment increase of 6% to $1.35B, Europe segment increase of 2% to $905M, Asia Pacific segment increase of 2% to $1.1B.
Odvětvová klasifikace
TRBC2012Advanced Medical Equipment & Technology (NEC)
RBSS2004Electrical Components & Equipment
MGINDUSTRYScientific & Technical Instr.
MGSECTORTechnology
NAICSAnalytical Laboratory Instrument Manufacturing
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSCustom Computer Programming Services
NAICSElectronic and Precision Equipment Repair and Maintenance
NAICS2007Analytical Laboratory Instrument Mfg
NAICS2007Electromedical Apparatus Mfg
NAICS1997Analytical Laboratory Instrument Manufacturing
NAICS1997Electromedical and Electrotherapeutic Apparatus Manufacturing
SICInstruments To Measure Electric
SICAnalytical Instruments
SICElectromedical Equipment
SICCommercial Physical Research
SICComputer Programming Services
SICComputer Maintenance & Repair



  • Poslední aktualizace: 07.06.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, DirectorPadraig Mcdonnell5301.05.202401.05.2020
Chief Financial Officer, Senior Vice PresidentRobert Mcmahon5601.09.201803.08.2018
Senior Vice President, Chief Legal Officer, SecretaryBret Dimarco5601.07.202401.07.2024
Senior Vice President, Agilent and Chief Commercial Officer, Commercial OrganizationJonah Kirkwood44
Senior Vice President, President, Diagnostics and GenomicsSimon May5306.05.202406.05.2024
Senior Vice President, Agilent and President, Agilent CrossLabAngelica Reimann-
Chief Technology OfficerAugust Specht-09.06.202509.06.2025
Chief Accounting Officer, Vice President, Corporate ControllershipRodney Gonsalves5907.05.201507.05.2015
Investment ManagerJudy Brown5620.05.202520.05.2025